A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin. These regimens offer no advance over current treatment.
D000230:Adenocarcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage*; D011379:Prognosis; D011929:Razoxane / Q000008:administration & dosage* / Q000009:adverse effects; D012004:Rectal Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy
D010879:Piperazines; D011929:Razoxane; D004317:Doxorubicin; D005472:Fluorouracil